Bicycle Therapeutics PLC (NAS:BCYC)
$ 21.6 -0.11 (-0.51%) Market Cap: 822.38 Mil Enterprise Value: 413.39 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 69/100

Bicycle Therapeutics PLC at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 02:10PM GMT
Release Date Price: $21.17 (-7.27%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

(technical difficulty) Morgan Stanley Global Healthcare conference, I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Bicycle Therapeutics with CEO, Kevin Lee; Chief Development Officer, Santiago Arroyo; Head of Commercial, Jennifer Perry. Welcome.

Kevin Lee
Bicycle Therapeutics plc - Director

Thanks. Good to be here.

Questions & Answers

Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

So for those who may not be familiar with Bicycle, can you provide a brief introduction?

Kevin Lee
Bicycle Therapeutics plc - Director

Sure. Bicycle is a company that works on a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot